ArticleHealthcare (Basel, Switzerland)2021
COVID-19 Disease Leading to Chronic Spontaneous Urticaria Exacerbation: A Romanian Retrospective Study.
Article in Healthcare (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Hereditary angioedema in children: Review and practical perspective for clinical management.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2024Review
- The Aftermath of COVID-19: Exploring the Long-Term Effects on Organ Systems.Biomedicines · 2024Review
- The Alarmin Triad-IL-25, IL-33, and TSLP-Serum Levels and Their Clinical Implications in Chronic Spontaneous Urticaria.International journal of molecular sciences · 2024Article
- Dermatologic Changes in Experimental Model of Long COVID.Microorganisms · 2024Article
- Phototherapy as an alternative in the treatment of chronic spontaneous urticaria.Frontiers in allergy · 2024Review
- New-onset chronic spontaneous urticaria post-COVID-19 vaccination-South African case series.The journal of allergy and clinical immunology. Global · 2023Article
- COVID-19 and Laboratory Markers from Romanian Patients-A Narrative Review.Life (Basel, Switzerland) · 2023Review
- How Infection and Vaccination Are Linked to Acute and Chronic Urticaria: A Special Focus on COVID-19.Viruses · 2023Review
- Long-Term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?Dermatology practical & conceptual · 2023Article
- Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report.Journal of medical case reports · 2023Article
- The effect of COVID-19 on patients recieving omalizumab treatment.Revue francaise d'allergologie (2009) · 2023Article
- A retrospective study regarding the influence of COVID-19 disease on asthma.BMC pulmonary medicine · 2023Article
- Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS.Journal of clinical medicine · 2022Article
- Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy.The Journal of allergy and clinical immunology · 2022Review
- Perinatal/maternal-fetal-infant dermatologic manifestations of SARS-CoV-2. An Overview and Implications for diagnosis, treatment, and prognosis.Frontiers in pediatrics · 2022Review
- Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic.Frontiers in allergy · 2022Review
- Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report.BioNanoScience · 2022Article
- Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.Journal of inflammation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: The COVID-19 pandemic has resulted in the exacerbation of various chronic diseases. Due to the potential impact of SARS-CoV-2 on mast cells, we aimed to analyze the relevance of COVID-19 disease on chronic spontaneous urticaria (CSU) clinical presentation and biological profile. (2) Methods: This study is a retrospective case series of patients with CSU diagnosed and treated in the Allergy Department of the Professor Doctor Octavian Fodor RIGH, (Cluj-Napoca, Romania). Patients were assessed for disease activity and level of control with the weekly urticaria activity score and the visual analogue scale. Results were correlated with COVID-19 severity and with nonspecific markers of inflammation during and after the SARS-CoV-2 infection. (3) Results: SARS-CoV-2 impacted a significant proportion (33%) of the CSU patients, of which 71% developed a moderate-severe form of COVID-19. Most of the patients (68%) had moderate-severe forms of CSU and 65% took AH1 treatment (one dose, two-fold dose or four-fold dose). The rest of them (35%) received the second-line treatment (40.3% Omalizumab, 53% Prednisolone and 4.8% Cyclosporine). In Omalizumab treated group of UCS patients we observed that COVID-19 disease was not severe. We established a positive correlation between the severity of the infection and that of the CSU clinical presentation, with most bothersome symptoms of urticaria being experienced by moderate to severe COVID-19 CSU patients (47%). Inflammatory markers were positively correlated (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.